- call +1-201-465-4211
- email sales@mrinsights.biz
Acute myeloid leukemia is the second frequent type (after acute lymphocytic leukemia) of leukemia diagnosed in infants. About 15% of children from birth to 19 years of age diagnosed with leukemia have acute myeloid leukemia. The risk of acute myeloid leukemia is closely associated with age. About 90% of acute myeloid leukemia is diagnosed in middle age. Incidence rate of acute myeloid leukemia is high in men and women over 50 years.
Scope of the Report:
This report studies the Acute Myeloid Leukemia Therapeutics market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Acute Myeloid Leukemia Therapeutics market by product type and applications/end industries.
Geographically, acute myeloid leukemia therapeutics market is divided into North America, Europe, Asia Pacific, Latin America, and MEA. As of 2014, North America held substantial share of the acute myeloid leukemia therapeutics market owing to prominent growth factors including rising incidences of acute myeloid leukemia and increasing geriatric population. Furthermore, advanced healthcare infrastructure, rising need of targeted therapies, huge investment in the development of pipeline drugs, and awareness amongst the population base induced market growth in this region. Asia Pacific is expected to be the fastest growing region over the forecast period owing to growth factors such as rising investments, rising disposable incomes, increasing cancer awareness, and improving healthcare infrastructure. Additionally, increasing inclination towards therapies such as targeted therapies resulting in low collateral damage and stronger efficacy is also anticipated to propel the demand for the acute myeloid leukemia therapeutics market in this region.
The global Acute Myeloid Leukemia Therapeutics market is valued at xx million USD in 2017 and is expected to reach xx million USD by the end of 2023, growing at a CAGR of xx% between 2017 and 2023.
The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions.
North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of Acute Myeloid Leukemia Therapeutics.
Europe also play important roles in global market, with market size of xx million USD in 2017 and will be xx million USD in 2023, with a CAGR of xx%.
Market Segment by Companies, this report covers
Ambit Biosciences Corporation
Genzyme Corporation Celgene Corporation
Clavis Pharma ASA
Sunesis Pharmaceuticals Inc.
Cephalon Inc.
Bristol-Myers Squibb
Novartis International AG
GlaxoSmithKline
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
Pipeline Drugs
Chemotherapy Drugs
Chemotherapy Regimens
Market Segment by Applications, can be divided into
Hospitals
Clinics
Home Care
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
Table of Contents
1 Acute Myeloid Leukemia Therapeutics Market Overview
1.1 Product Overview and Scope of Acute Myeloid Leukemia Therapeutics
1.2 Classification of Acute Myeloid Leukemia Therapeutics by Types
1.2.1 Global Acute Myeloid Leukemia Therapeutics Revenue Comparison by Types (2017-2023)
1.2.2 Global Acute Myeloid Leukemia Therapeutics Revenue Market Share by Types in 2017
1.2.3 Pipeline Drugs
1.2.4 Chemotherapy Drugs
1.2.5 Chemotherapy Regimens
1.3 Global Acute Myeloid Leukemia Therapeutics Market by Application
1.3.1 Global Acute Myeloid Leukemia Therapeutics Market Size and Market Share Comparison by Applications (2013-2023)
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Home Care
1.4 Global Acute Myeloid Leukemia Therapeutics Market by Regions
1.4.1 Global Acute Myeloid Leukemia Therapeutics Market Size (Million USD) Comparison by Regions (2013-2023)
1.4.1 North America (USA, Canada and Mexico) Acute Myeloid Leukemia Therapeutics Status and Prospect (2013-2023)
1.4.2 Europe (Germany, France, UK, Russia and Italy) Acute Myeloid Leukemia Therapeutics Status and Prospect (2013-2023)
1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Acute Myeloid Leukemia Therapeutics Status and Prospect (2013-2023)
1.4.4 South America (Brazil, Argentina, Colombia) Acute Myeloid Leukemia Therapeutics Status and Prospect (2013-2023)
1.4.5 Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Acute Myeloid Leukemia Therapeutics Status and Prospect (2013-2023)
1.5 Global Market Size of Acute Myeloid Leukemia Therapeutics (2013-2023)
2 Manufacturers Profiles
2.1 Ambit Biosciences Corporation
2.1.1 Business Overview
2.1.2 Acute Myeloid Leukemia Therapeutics Type and Applications
2.1.2.1 Product A
2.1.2.2 Product B
2.1.3 Ambit Biosciences Corporation Acute Myeloid Leukemia Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.2 Genzyme Corporation Celgene Corporation
2.2.1 Business Overview
2.2.2 Acute Myeloid Leukemia Therapeutics Type and Applications
2.2.2.1 Product A
2.2.2.2 Product B
2.2.3 Genzyme Corporation Celgene Corporation Acute Myeloid Leukemia Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.3 Clavis Pharma ASA
2.3.1 Business Overview
2.3.2 Acute Myeloid Leukemia Therapeutics Type and Applications
2.3.2.1 Product A
2.3.2.2 Product B
2.3.3 Clavis Pharma ASA Acute Myeloid Leukemia Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.4 Sunesis Pharmaceuticals Inc.
2.4.1 Business Overview
2.4.2 Acute Myeloid Leukemia Therapeutics Type and Applications
2.4.2.1 Product A
2.4.2.2 Product B
2.4.3 Sunesis Pharmaceuticals Inc. Acute Myeloid Leukemia Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.5 Cephalon Inc.
2.5.1 Business Overview
2.5.2 Acute Myeloid Leukemia Therapeutics Type and Applications
2.5.2.1 Product A
2.5.2.2 Product B
2.5.3 Cephalon Inc. Acute Myeloid Leukemia Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.6 Bristol-Myers Squibb
2.6.1 Business Overview
2.6.2 Acute Myeloid Leukemia Therapeutics Type and Applications
2.6.2.1 Product A
2.6.2.2 Product B
2.6.3 Bristol-Myers Squibb Acute Myeloid Leukemia Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.7 Novartis International AG
2.7.1 Business Overview
2.7.2 Acute Myeloid Leukemia Therapeutics Type and Applications
2.7.2.1 Product A
2.7.2.2 Product B
2.7.3 Novartis International AG Acute Myeloid Leukemia Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.8 GlaxoSmithKline
2.8.1 Business Overview
2.8.2 Acute Myeloid Leukemia Therapeutics Type and Applications
2.8.2.1 Product A
2.8.2.2 Product B
2.8.3 GlaxoSmithKline Acute Myeloid Leukemia Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
3 Global Acute Myeloid Leukemia Therapeutics Market Competition, by Players
3.1 Global Acute Myeloid Leukemia Therapeutics Revenue and Share by Players (2013-2018)
3.2 Market Concentration Rate
3.2.1 Top 5 Acute Myeloid Leukemia Therapeutics Players Market Share
3.2.2 Top 10 Acute Myeloid Leukemia Therapeutics Players Market Share
3.3 Market Competition Trend
4 Global Acute Myeloid Leukemia Therapeutics Market Size by Regions
4.1 Global Acute Myeloid Leukemia Therapeutics Revenue and Market Share by Regions
4.2 North America Acute Myeloid Leukemia Therapeutics Revenue and Growth Rate (2013-2018)
4.3 Europe Acute Myeloid Leukemia Therapeutics Revenue and Growth Rate (2013-2018)
4.4 Asia-Pacific Acute Myeloid Leukemia Therapeutics Revenue and Growth Rate (2013-2018)
4.5 South America Acute Myeloid Leukemia Therapeutics Revenue and Growth Rate (2013-2018)
4.6 Middle East and Africa Acute Myeloid Leukemia Therapeutics Revenue and Growth Rate (2013-2018)
5 North America Acute Myeloid Leukemia Therapeutics Revenue by Countries
5.1 North America Acute Myeloid Leukemia Therapeutics Revenue by Countries (2013-2018)
5.2 USA Acute Myeloid Leukemia Therapeutics Revenue and Growth Rate (2013-2018)
5.3 Canada Acute Myeloid Leukemia Therapeutics Revenue and Growth Rate (2013-2018)
5.4 Mexico Acute Myeloid Leukemia Therapeutics Revenue and Growth Rate (2013-2018)
6 Europe Acute Myeloid Leukemia Therapeutics Revenue by Countries
6.1 Europe Acute Myeloid Leukemia Therapeutics Revenue by Countries (2013-2018)
6.2 Germany Acute Myeloid Leukemia Therapeutics Revenue and Growth Rate (2013-2018)
6.3 UK Acute Myeloid Leukemia Therapeutics Revenue and Growth Rate (2013-2018)
6.4 France Acute Myeloid Leukemia Therapeutics Revenue and Growth Rate (2013-2018)
6.5 Russia Acute Myeloid Leukemia Therapeutics Revenue and Growth Rate (2013-2018)
6.6 Italy Acute Myeloid Leukemia Therapeutics Revenue and Growth Rate (2013-2018)
7 Asia-Pacific Acute Myeloid Leukemia Therapeutics Revenue by Countries
7.1 Asia-Pacific Acute Myeloid Leukemia Therapeutics Revenue by Countries (2013-2018)
7.2 China Acute Myeloid Leukemia Therapeutics Revenue and Growth Rate (2013-2018)
7.3 Japan Acute Myeloid Leukemia Therapeutics Revenue and Growth Rate (2013-2018)
7.4 Korea Acute Myeloid Leukemia Therapeutics Revenue and Growth Rate (2013-2018)
7.5 India Acute Myeloid Leukemia Therapeutics Revenue and Growth Rate (2013-2018)
7.6 Southeast Asia Acute Myeloid Leukemia Therapeutics Revenue and Growth Rate (2013-2018)
8 South America Acute Myeloid Leukemia Therapeutics Revenue by Countries
8.1 South America Acute Myeloid Leukemia Therapeutics Revenue by Countries (2013-2018)
8.2 Brazil Acute Myeloid Leukemia Therapeutics Revenue and Growth Rate (2013-2018)
8.3 Argentina Acute Myeloid Leukemia Therapeutics Revenue and Growth Rate (2013-2018)
8.4 Colombia Acute Myeloid Leukemia Therapeutics Revenue and Growth Rate (2013-2018)
9 Middle East and Africa Revenue Acute Myeloid Leukemia Therapeutics by Countries
9.1 Middle East and Africa Acute Myeloid Leukemia Therapeutics Revenue by Countries (2013-2018)
9.2 Saudi Arabia Acute Myeloid Leukemia Therapeutics Revenue and Growth Rate (2013-2018)
9.3 UAE Acute Myeloid Leukemia Therapeutics Revenue and Growth Rate (2013-2018)
9.4 Egypt Acute Myeloid Leukemia Therapeutics Revenue and Growth Rate (2013-2018)
9.5 Nigeria Acute Myeloid Leukemia Therapeutics Revenue and Growth Rate (2013-2018)
9.6 South Africa Acute Myeloid Leukemia Therapeutics Revenue and Growth Rate (2013-2018)
10 Global Acute Myeloid Leukemia Therapeutics Market Segment by Type
10.1 Global Acute Myeloid Leukemia Therapeutics Revenue and Market Share by Type (2013-2018)
10.2 Global Acute Myeloid Leukemia Therapeutics Market Forecast by Type (2018-2023)
10.3 Pipeline Drugs Revenue Growth Rate (2013-2023)
10.4 Chemotherapy Drugs Revenue Growth Rate (2013-2023)
10.5 Chemotherapy Regimens Revenue Growth Rate (2013-2023)
11 Global Acute Myeloid Leukemia Therapeutics Market Segment by Application
11.1 Global Acute Myeloid Leukemia Therapeutics Revenue Market Share by Application (2013-2018)
11.2 Acute Myeloid Leukemia Therapeutics Market Forecast by Application (2018-2023)
11.3 Hospitals Revenue Growth (2013-2018)
11.4 Clinics Revenue Growth (2013-2018)
11.5 Home Care Revenue Growth (2013-2018)
12 Global Acute Myeloid Leukemia Therapeutics Market Size Forecast (2018-2023)
12.1 Global Acute Myeloid Leukemia Therapeutics Market Size Forecast (2018-2023)
12.2 Global Acute Myeloid Leukemia Therapeutics Market Forecast by Regions (2018-2023)
12.3 North America Acute Myeloid Leukemia Therapeutics Revenue Market Forecast (2018-2023)
12.4 Europe Acute Myeloid Leukemia Therapeutics Revenue Market Forecast (2018-2023)
12.5 Asia-Pacific Acute Myeloid Leukemia Therapeutics Revenue Market Forecast (2018-2023)
12.6 South America Acute Myeloid Leukemia Therapeutics Revenue Market Forecast (2018-2023)
12.7 Middle East and Africa Acute Myeloid Leukemia Therapeutics Revenue Market Forecast (2018-2023)
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Data Source
List of Tables and Figures
Figure Acute Myeloid Leukemia Therapeutics Picture
Table Product Specifications of Acute Myeloid Leukemia Therapeutics
Table Global Acute Myeloid Leukemia Therapeutics and
ProactiveWe manage our resources 24/7 to identify issues and address them before they become problems
Quality & ReliabilityWe are committed to providing reliable and highly accurate data with an excellent quality control system
Global Outreach6 Major regions and 40+ countries level analysis accomplished
Competitive PricingOur pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery
